Simvastatin, a potential therapeutic drug for colorectal cancer immunotherapy, promotes anti-tumor immunity by inhibiting lncRNA SNHG29-mediated YAP activation and inhibiting PD-L1 expression (188). The gene discussed is YAP1; the disease is colorectal cancer.